Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer.

@article{Belani1995PaclitaxelAC,
  title={Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer.},
  author={Chandra Prakash Belani and Joseph Aisner and D J Hiponia and Christine Engstrom},
  journal={Seminars in oncology},
  year={1995},
  volume={22 4 Suppl 9},
  pages={7-12}
}
Paclitaxel (Taxol; Bristol-Myers Squibb Oncology, Princeton, NJ) and carboplatin have each shown activity against non-small cell lung cancer and they are synergistic in vitro. We thus designed a phase I study to define the maximum tolerated dose and dose-limiting toxicity of the combination with and without filgrastim support. With an initial fixed dose of… CONTINUE READING